Laboratory biomarkers of an effective antitumor immune response. Clinical significance.

Autor: Malkova AM; Saint Petersburg State University, 7/9 Universitetskaya Emb., St Petersburg 199034, Russian Federation. Electronic address: anya.malkova.95@mail.ru., Sharoyko VV; Saint Petersburg State University, 7/9 Universitetskaya Emb., St Petersburg 199034, Russian Federation. Electronic address: sharoyko@gmail.com., Zhukova NV; Saint Petersburg State University, 7/9 Universitetskaya Emb., St Petersburg 199034, Russian Federation. Electronic address: natalia-zhukova@yandex.ru., Gubal AR; Saint Petersburg State University, 7/9 Universitetskaya Emb., St Petersburg 199034, Russian Federation. Electronic address: a.r.gubal@spbu.ru., Orlova RV; Saint Petersburg State University, 7/9 Universitetskaya Emb., St Petersburg 199034, Russian Federation. Electronic address: orlova_rashida@mail.ru.
Jazyk: angličtina
Zdroj: Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 29, pp. 100489. Date of Electronic Publication: 2021 Nov 16.
DOI: 10.1016/j.ctarc.2021.100489
Abstrakt: The modern checkpoint inhibitors block the programmed death-1 receptor and its ligand, cytotoxic T-lymphocyte-associated antigen 4 on tumor cells and lymphocytes, that induces cytotoxic reactions. Nowadays, there are no approved clinical and laboratory predictor markers of immune therapy efficacy, which would allow a more personalized approach to patient selection and treatment. The aim of this review is to analyze possible biomarkers of efficacy for treatment with checkpoint inhibitors according to the pathogenic mechanisms of drug action. The review revealed possible predictive biomarkers, that could be classified to 3 groups: biomarkers of high mutagenic potential of the tumor, biomarkers of high activity of adaptive immunity, biomarkers of low activity of the tumor microenvironment. The determination of the described markers before the start of therapy can be used to formulate a treatment regimen, in which the use of various immunomodulatory drugs, inhibitors of proinflammatory cytokines, angiogenic molecules, and probiotics can be considered.
(Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: